Literature DB >> 21926036

TLR expression in human melanoma cells.

Mélanie Saint-Jean1, Anne-Chantal Knol, Jean-Michel Nguyen, Amir Khammari, Brigitte Dréno.   

Abstract

UNLABELLED: There is increasing evidence that melanoma cells express TLR2, -3, and -4. However, the expression of other TLRs by these cells still remains unknown. We investigated the expression patterns of TLR2, -3, -4, -7, -8 and -9 both on melanoma-invaded lymph nodes and on melanoma cell lines. TLR2, -3, -4, -7 and -9 mRNA expression was determined by quantitative RT-PCR. The TLR protein expression level was measured ex vivo by immunohistochemistry and in vitro by flow cytometry.
RESULTS: At the mRNA level, melanoma cells in vitro, and possibly ex vivo, expressed TLR2, -3, -4, -7 and -9. TLR2 and -4 protein expressions ex vivo were over 50%, contrasting with an absence of these 2 TLRs in vitro. On the contrary, TLR-3 and -8 proteins had a low expression ex vivo with a high expression in vitro. TLR-7 and -9 proteins were expressed ex vivo and in vitro. Our study demonstrates for the first time that melanoma cells express TLR7 and -8.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926036     DOI: 10.1684/ejd.2011.1526

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  13 in total

Review 1.  Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.

Authors:  Eileena F Giurini; Mary Beth Madonna; Andrew Zloza; Kajal H Gupta
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

2.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

3.  Baicalin Protects Keratinocytes from Toll-like Receptor-4 Mediated DNA Damage and Inflammation Following Ultraviolet Irradiation.

Authors:  Wei Min; Israr Ahmad; Michelle E Chang; Erin M Burns; Qihong Qian; Nabiha Yusuf
Journal:  Photochem Photobiol       Date:  2015-09-11       Impact factor: 3.421

4.  TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.

Authors:  Lisa Elefanti; Giorgia Sacco; Camilla Stagni; Marco Rastrelli; Chiara Menin; Irene Russo; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

5.  Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4.

Authors:  Ratika Srivastava; Degui Geng; Yingjia Liu; Liqin Zheng; Zhaoyang Li; Mary Ann Joseph; Colleen McKenna; Navneeta Bansal; Augusto Ochoa; Eduardo Davila
Journal:  Cancer Res       Date:  2012-10-04       Impact factor: 12.701

Review 6.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

7.  The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.

Authors:  Jeong Hyun Cho; Hyo-Ji Lee; Hyun-Jeong Ko; Byung-Il Yoon; Jongseon Choe; Keun-Cheol Kim; Tae-Wook Hahn; Jeong A Han; Sun Shim Choi; Young Mee Jung; Kee-Ho Lee; Yun-Sil Lee; Yu-Jin Jung
Journal:  Oncotarget       Date:  2017-04-11

Review 8.  The Role of TLRs in Anti-cancer Immunity and Tumor Rejection.

Authors:  Zuzanna Urban-Wojciuk; Mohd M Khan; Benjamin L Oyler; Robin Fåhraeus; Natalia Marek-Trzonkowska; Aleksandra Nita-Lazar; Ted R Hupp; David R Goodlett
Journal:  Front Immunol       Date:  2019-10-22       Impact factor: 7.561

Review 9.  Toll-like receptors and skin cancer.

Authors:  Erin M Burns; Nabiha Yusuf
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

Review 10.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.